I'll analyze the DLL3-targeted competitive landscape in ES-SCLC. Let me start by exploring the database.
{
"indications": {
"ES-SCLC": {
"targets": [
"DLL3",
"PD-L1",
"SEZ6"
],
"n_trials": 7
},
"Gastric/GEJ": {
"targets": [
"CLDN18.2",
"PD-1"
],
"n_trials": 7
},
"HER2+ Breast": {
"targets": [
"HER2"
],
"n_trials": 5
},
"HER2-low Breast": {
"targets": [
"HER2"
],
"n_trials": 1
}
}
}{
"count": 4,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
}
]
}Let me get the full records for these trials and look at the broader ES-SCLC landscape (other targets) for context.
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
}{
"count": 7,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
},
{
"nct": "NCT04471727",
"sponsor": "AbbVie",
"drug": "ABBV-011 (SC-002 / SEZ6 ADC)",
"indication": "ES-SCLC",
"target": "SEZ6",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 130,
"start_year": 2020,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT03043872",
"sponsor": "Roche/Genentech",
"drug": "Atezolizumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 403,
"start_year": 2016,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03066778",
"sponsor": "AstraZeneca",
"drug": "Durvalumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 537,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}
]
}I now have the full picture. Here's my competitive analysis.
| Sponsor | Asset | Modality | Phase | N | Start | Endpoint | Control |
|---|---|---|---|---|---|---|---|
| Amgen | Tarlatamab (AMG 757) | BiTE (T-cell engager) | Ph3 | 600 | 2022 | OS | Chemo |
| Amgen | Tarlatamab (AMG 757) | BiTE | Ph2 | 220 | 2018 | ORR | Single-arm |
| Boehringer Ingelheim | Obrixtamig (BI 764532) | BiTE | Ph2 | 180 | 2022 | ORR | Single-arm |
| Legend Biotech | LB2102 | Autologous CAR-T | Ph1 | 40 | 2023 | DLT/safety | Single-arm |
All four DLL3 trials sit in the 2L+ setting.
Amgen owns the category on every axis that matters:
The practical implication: tarlatamab is positioned to define the standard of care and the regulatory/comparator benchmark for the entire DLL3 class. Any later entrant will likely be measured against tarlatamab, not chemo.
By modality — two strategic camps:
By endpoint/rigor: Only Amgen's Ph3 uses OS vs. control. The other three are ORR or safety, single-arm — i.e., signal-finding, not confirmatory.
The crowding is concentrated and the gaps are conspicuous:
1L is wide open. Every DLL3 trial is 2L+. First-line ES-SCLC is currently owned by PD-L1 + chemo (atezolizumab/IMpower133, durvalumab/CASPIAN — both completed Ph3). No one is testing DLL3 agents in the frontline or as maintenance after chemo-IO induction — arguably the biggest unclaimed value pool, given the short duration of 1L responses.
DLL3 + checkpoint-inhibitor combinations are absent. With PD-L1 entrenched in 1L, a tarlatamab/obrixtamig + anti–PD-L1 combination (induction or maintenance) is an obvious unexplored strategy — none in the database.
No DLL3 ADC in ES-SCLC here. Note AbbVie's ABBV-011 is an ADC but against SEZ6, not DLL3. (Historically Rova-T, a DLL3 ADC, failed — so the ADC-vs-DLL3 lane is open but reputationally scarred.) An ADC could complement T-cell engagers in CD3-engager–refractory patients.
Earlier-line / limited-stage and maintenance settings are untouched by DLL3 agents generally.
DLL3-biomarker–selected / antigen-escape strategies: no apparent program addressing DLL3-low or post-tarlatamab relapse — a future need once 2L tarlatamab becomes standard.
Amgen leads decisively with the only Phase 3, OS-powered, first-mover program — tarlatamab is on track to become the class-defining standard in 2L+. Boehringer's obrixtamig is a same-modality fast-follower needing a differentiation story; Legend's CAR-T is the high-risk/high-reward mechanistic wildcard. The strategic whitespace is not in 2L+ BiTEs (crowded) but in 1L/maintenance positioning, DLL3 + checkpoint combinations, and post–T-cell-engager relapse — settings no one in this dataset is yet contesting.
Caveat: this reflects the trials in this database; a full landscape read would also confirm against ClinicalTrials.gov for additional DLL3 assets (e.g., other ADCs/trispecifics) and ongoing 1L moves.
I now have the full picture. Here's my competitive analysis.
| Sponsor | Asset | Modality | Phase | N | Start | Endpoint | Control |
|---|---|---|---|---|---|---|---|
| Amgen | Tarlatamab (AMG 757) | BiTE (T-cell engager) | Ph3 | 600 | 2022 | OS | Chemo |
| Amgen | Tarlatamab (AMG 757) | BiTE | Ph2 | 220 | 2018 | ORR | Single-arm |
| Boehringer Ingelheim | Obrixtamig (BI 764532) | BiTE | Ph2 | 180 | 2022 | ORR | Single-arm |
| Legend Biotech | LB2102 | Autologous CAR-T | Ph1 | 40 | 2023 | DLT/safety | Single-arm |
All four DLL3 trials sit in the 2L+ setting.
Amgen owns the category on every axis that matters:
The practical implication: tarlatamab is positioned to define the standard of care and the regulatory/comparator benchmark for the entire DLL3 class. Any later entrant will likely be measured against tarlatamab, not chemo.
By modality — two strategic camps:
By endpoint/rigor: Only Amgen's Ph3 uses OS vs. control. The other three are ORR or safety, single-arm — i.e., signal-finding, not confirmatory.
The crowding is concentrated and the gaps are conspicuous:
1L is wide open. Every DLL3 trial is 2L+. First-line ES-SCLC is currently owned by PD-L1 + chemo (atezolizumab/IMpower133, durvalumab/CASPIAN — both completed Ph3). No one is testing DLL3 agents in the frontline or as maintenance after chemo-IO induction — arguably the biggest unclaimed value pool, given the short duration of 1L responses.
DLL3 + checkpoint-inhibitor combinations are absent. With PD-L1 entrenched in 1L, a tarlatamab/obrixtamig + anti–PD-L1 combination (induction or maintenance) is an obvious unexplored strategy — none in the database.
No DLL3 ADC in ES-SCLC here. Note AbbVie's ABBV-011 is an ADC but against SEZ6, not DLL3. (Historically Rova-T, a DLL3 ADC, failed — so the ADC-vs-DLL3 lane is open but reputationally scarred.) An ADC could complement T-cell engagers in CD3-engager–refractory patients.
Earlier-line / limited-stage and maintenance settings are untouched by DLL3 agents generally.
DLL3-biomarker–selected / antigen-escape strategies: no apparent program addressing DLL3-low or post-tarlatamab relapse — a future need once 2L tarlatamab becomes standard.
Amgen leads decisively with the only Phase 3, OS-powered, first-mover program — tarlatamab is on track to become the class-defining standard in 2L+. Boehringer's obrixtamig is a same-modality fast-follower needing a differentiation story; Legend's CAR-T is the high-risk/high-reward mechanistic wildcard. The strategic whitespace is not in 2L+ BiTEs (crowded) but in 1L/maintenance positioning, DLL3 + checkpoint combinations, and post–T-cell-engager relapse — settings no one in this dataset is yet contesting.
Caveat: this reflects the trials in this database; a full landscape read would also confirm against ClinicalTrials.gov for additional DLL3 assets (e.g., other ADCs/trispecifics) and ongoing 1L moves.
Deterministic summary over the curated trial set for the queried indication. A strong agent should recover the leaders, the phase/modality mix, and credible whitespace.
| Metric | Value | Note |
|---|---|---|
| Trials in scope | 7 | indication = ES-SCLC |
| By phase | PHASE1:2, PHASE2:2, PHASE3:3 | |
| By modality | T-cell engager (BiTE):3; Checkpoint inhibitor (mAb):2; CAR-T (autologous):1; Antibody-drug conjugate:1 | |
| Top sponsors | Amgen:2; Boehringer Ingelheim:1; Legend Biotech:1 | |
| Whitespace (modality @ line, no active trial) | Antibody-drug conjugate @ 1L; CAR-T (autologous) @ 1L; Checkpoint inhibitor (mAb) @ 1L; Checkpoint inhibitor (mAb) @ 2L+; T-cell engager (BiTE) @ 1L |